Bayer to Discontinue Phase II Clinical Trial for Recombinant Factor VIII

January 25, 2010
Bayer Schering Pharma AG, Germany has announced that an independent Data Safety and Monitoring Board has completed an interim analysis of a phase II trial (the LIPLONG study) of the company’s long-acting recombinant factor VIII, BAY79-4980.
The Financial